RXi Pharmaceuticals $RXII signed an exclusive option agreement to acquire all outstanding capital stock of privately held Mirlmmune. As per the terms of the agreement, RXi would issue stock equal to 19.99% of its outstanding shares along with additional consideration tied to milestones. It can exercise the option until April 5, 2017. Mirlmmune is developing next-generation therapeutics in immune-oncology based in adoptive cell transfer. Both companies have existing relationship. Earlier in 2015, both signed an exclusive deal related to RXs�s self-delivering RNAi technology.